Activation of the ERK cascade is pervasive across various cancer types, with phosphorylated ERK1/2 (p-ERK1/2) present in over 90% of HNSCC patients [37, 38]. This evidence concerns the gene MAPK3 and head and neck squamous cell carcinoma.